Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 2/20 | 0.52 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.52 |
| ▸ | SCD5 | Q86SK9 | 7/20 | 0.49 |
| ▸ | SCD | O00767 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173881 | 0.97 | TRPC3 (0.56) | TRPC3TRPC6SCD5SCDSCN9A | |
| SCHEMBL4165060 | 0.97 | TRPC3 (0.55) | TRPC3TRPC6SCD5SCDSCN9A | |
| SCHEMBL4176159 | 0.89 | TRPC3 (0.61) | TRPC3TRPC6SCD5SCDSCN9A | |
| SCHEMBL4172599 | 0.89 | TRPC3 (0.61) | TRPC3TRPC6SCD5SCDSCN9A | |
| SCHEMBL4178010 | 0.86 | TRPC3 (0.51) | TRPC3TRPC6KDM1AMAOA | |
| SCHEMBL4165105 | 0.86 | TRPC3 (0.66) | TRPC3TRPC6SCD5SCDSCN9A | |
| SCHEMBL4170692 | 0.85 | TRPC3 (0.65) | TRPC3TRPC6SCD5SCDSCN9A | |
| SCHEMBL4180247 | 0.85 | TRPC3 (0.56) | TRPC3TRPC6SCD5SCDSCN9A | |
| SCHEMBL4176165 | 0.84 | SCN9A (0.49) | TRPC3TRPC6SCD5SCN9AROCK2 | |
| SCHEMBL4181512 | 0.82 | TRPC3 (0.71) | TRPC3TRPC6SCD5SCDSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | TRPC3 57/4885TRPC6 84/4885SCD5 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.